PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24949876-4	2014	hRFC transcripts and the total membrane protein increased with increasing LCV [(6R,S)5-formyl tetrahydrofolate (leucovorin)] with a maximum at 20 nM LCV, attributable to reduced turnover of hRFC transcripts.	leucogentian violet	74-77	solute carrier family 19 member 1	Homo sapiens	0-4
32009251-9	2020	Consistent with the established mechanisms of LCV-related lymphoproliferation, MYC and BCL2L11 gene expression were increased and decreased, respectively.	leucogentian violet	46-49	myc proto-oncogene protein	Macaca fascicularis	79-82
32009251-9	2020	Consistent with the established mechanisms of LCV-related lymphoproliferation, MYC and BCL2L11 gene expression were increased and decreased, respectively.	leucogentian violet	46-49	bcl-2-like protein 11	Macaca fascicularis	87-94
24949876-4	2014	hRFC transcripts and the total membrane protein increased with increasing LCV [(6R,S)5-formyl tetrahydrofolate (leucovorin)] with a maximum at 20 nM LCV, attributable to reduced turnover of hRFC transcripts.	leucogentian violet	149-152	solute carrier family 19 member 1	Homo sapiens	0-4
24949876-6	2014	Cell surface hRFC paralleled [3H]methotrexate transport and increased from 0.5 to 2 nM LCV, and then decreased (~2-fold) with increasing LCV up to 20 nM.	leucogentian violet	87-90	solute carrier family 19 member 1	Homo sapiens	13-17
24949876-6	2014	Cell surface hRFC paralleled [3H]methotrexate transport and increased from 0.5 to 2 nM LCV, and then decreased (~2-fold) with increasing LCV up to 20 nM.	leucogentian violet	137-140	solute carrier family 19 member 1	Homo sapiens	13-17
24949876-7	2014	hRFC was localized to the cell surface at low LCV concentrations (0.5-1.5 nM).	leucogentian violet	46-49	solute carrier family 19 member 1	Homo sapiens	0-4
24949876-8	2014	However, at higher LCV concentrations, significant intracellular hRFC was localized to the ER (endoplasmic reticulum), such that at 20 nM LCV, intracellular hRFC was predominated.	leucogentian violet	19-22	solute carrier family 19 member 1	Homo sapiens	65-69
24949876-8	2014	However, at higher LCV concentrations, significant intracellular hRFC was localized to the ER (endoplasmic reticulum), such that at 20 nM LCV, intracellular hRFC was predominated.	leucogentian violet	19-22	solute carrier family 19 member 1	Homo sapiens	157-161
24949876-8	2014	However, at higher LCV concentrations, significant intracellular hRFC was localized to the ER (endoplasmic reticulum), such that at 20 nM LCV, intracellular hRFC was predominated.	leucogentian violet	138-141	solute carrier family 19 member 1	Homo sapiens	65-69
17060682-2	2006	In the present study, we examined, using urethane-anesthetized rats, the dose-dependent effects of intravenous (iv) or intralateral cerebral ventricular (LCV) injection of various doses of orexin-A on RSNA and BP.	leucogentian violet	154-157	hypocretin neuropeptide precursor	Rattus norvegicus	189-197
17060682-3	2006	We found that injection of a low dose of orexin-A (10 ng iv or 0.01 ng LCV) suppressed RSNA and BP significantly.	leucogentian violet	71-74	hypocretin neuropeptide precursor	Rattus norvegicus	41-49
17060682-4	2006	Conversely, a high dose (1000 ng iv or 10 ng LCV) of orexin-A elevated both RSNA and BP significantly.	leucogentian violet	45-48	hypocretin neuropeptide precursor	Rattus norvegicus	53-61
17060682-5	2006	Pretreatment with either iv or LCV injection of thioperamide, a histaminergic H(3)-receptor antagonist, eliminated the effects of a low dose of orexin-A on both RSNA and BP.	leucogentian violet	31-34	hypocretin neuropeptide precursor	Rattus norvegicus	144-152
17060682-6	2006	Both iv and LCV injection of diphenhydramine, a histaminergic H(1)-receptor antagonist, abolished the effects of a high dose of orexin-A on RSNA and BP.	leucogentian violet	12-15	hypocretin neuropeptide precursor	Rattus norvegicus	128-136
8945729-2	1996	LCV injections of TNF-alpha at doses of 10 pg, 100 pg and 1 ng reduced paw withdrawal latency, showing a maximal response at a dose of 10 pg which peaked 60 min after injection.	leucogentian violet	0-3	tumor necrosis factor	Rattus norvegicus	18-27
6198451-4	1984	The premature loss of the gp70 molecule from LCV to the culture medium was ruled out since no peak of D-[14C]glucosamine-labelled glycoprotein was detected by affinity chromatography or immunoprecipitation of concentrated medium.	leucogentian violet	45-48	embigin	Mus musculus	26-30
6198451-7	1984	The absence of fluorescent stain in L929 cells further supported these results and suggested that LCV and the L929 parental cell line lack the uncleaved precursor and the final product of the env gene translation process.	leucogentian violet	98-101	melanoma antigen	Mus musculus	192-195